Comparison of contrast induced nephropathy between groups.
CIN, nephropathy
CONTRAST-INDUCED NEPHROPATHY, RENAL FAILURE, CIN, NEPHROPATHY, HEART FAILURE, TYPE 2 DIABETES
AR group: patients who received a reloading dose of 80 mg atorvastatin, Cys-CIN: Contrast-induced nephropathy based on cystatin C levels, NR group: patients who did not receive a reloading dose, Scr-CIN: contrast induced nephropathy based on Serum creatinine levels.The analysis of subgroups who are known as a high-risk CIN population (patients with renal failure, patients aged > 70 years, type 2 diabetes, patients with Mehran score > 10, patients with heart failure, patients on ACE/ARBs) showed a benefit of additional atorvastatin reloading only in the type 2 diabetes group. The CyC-based CIN in patients with type 2 diabetes was significantly lower in patients who received a reload dose of atorvastatin than those didn’t receive a reload dose of statin (18.8% vs 43.5%,p = 0.046, RR = 0.43, Confidence Interval 95% [0.18–0.99]) (